Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Equity (2022 - 2025)

Prime Medicine's Return on Equity history spans 4 years, with the latest figure at 1.45% for Q4 2025.

  • For Q4 2025, Return on Equity fell 31.0% year-over-year to 1.45%; the TTM value through Dec 2025 reached 1.45%, down 31.0%, while the annual FY2025 figure was 1.49%, 12.0% down from the prior year.
  • Return on Equity reached 1.45% in Q4 2025 per PRME's latest filing, up from 1.79% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.73% in Q2 2022 to a low of 2.61% in Q4 2022.
  • Average Return on Equity over 4 years is 1.05%, with a median of 1.14% recorded in 2024.
  • The largest YoY upside for Return on Equity was 140bps in 2023 against a maximum downside of -149bps in 2023.
  • A 4-year view of Return on Equity shows it stood at 2.61% in 2022, then surged by 54bps to 1.21% in 2023, then increased by 6bps to 1.14% in 2024, then fell by -27bps to 1.45% in 2025.
  • Per Business Quant, the three most recent readings for PRME's Return on Equity are 1.45% (Q4 2025), 1.79% (Q3 2025), and 2.38% (Q2 2025).